Sensipar Clinical Trials Sensipar RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)
Condition:   Primary Hyperparathyroidism Interventions:   Drug: Cinacalcet;   Drug: Placebo Sponsor:   Amgen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2018 Category: Research Source Type: clinical trials